RT Book, Section
A1 Dirkx, Tonja C.
A1 Woodell, Tyler B.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184183309
T1 Nephritic Spectrum Glomerular Diseases
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184183309
RD 2024/04/19
AB Key  Clinical  Updates  in  Nephritic  Spectrum  Glomerular  DiseasesPrior  trials  suggested  that  corticosteroids  reduced  proteinuria  when  administered  to  patients  with  GFR  >  50  mL/min/1.73  m2  and  persistent  proteinuria  >  1  g.  However,  more  recent  data  failed  to  demonstrate  slowing  of  GFR  loss  with  corticosteroid  therapy  compared  with  use  of  ACE  inhibitor  or  ARB  alone;  enthusiasm  for  glucocorticoid  therapy  therefore  has  waned.Trials  using  the  complement  inhibitor  avacopan  in  place  of  glucocorticoids  in  cyclophosphamide-  or  rituximab-based  regimens  are  ongoing  and  appear  promising.